Benralizumab + Placebo to Benralizumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-cystic Fibrosis Bronchiectasis
Conditions
Non-cystic Fibrosis Bronchiectasis
Trial Timeline
Jul 21, 2021 → Apr 16, 2024
NCT ID
NCT05006573About Benralizumab + Placebo to Benralizumab
Benralizumab + Placebo to Benralizumab is a phase 3 stage product being developed by AstraZeneca for Non-cystic Fibrosis Bronchiectasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05006573. Target conditions include Non-cystic Fibrosis Bronchiectasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05006573 | Phase 3 | Terminated |
Competing Products
8 competing products in Non-cystic Fibrosis Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 52 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 2 | 49 |
| Brensocatib | Insmed | Pre-clinical | 20 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 3 | 74 |
| AP-PA02 | Armata Pharmaceuticals | Phase 2 | 44 |